Skip to main content
Fig. 2 | BMC Medical Research Methodology

Fig. 2

From: The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Fig. 2

RCT evidence network: Each node represents a treatment regimen and connections between nodes indicate comparative RCT evidence. Interventions licensed in Europe are highlighted in grey. bev = bevacizumab; bor = bortezomib; carf = carfilzomib; cyc = cyclophosphamide; dara = daratumumab; dex = dexamethasone; elo = elozumatab; IFN = interferon alpha; ixa = ixazomib; len = lenalidomide; ob = oblimersen; pan = panobinostat; peri = perifosine; PLD = pegylated liposomal doxorubicin; pom = pomalidomide; sil = silituximab; thal = thalidomide; vor = vorinostat

Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us